BioPharm International - November 2022

BioPharm International - November 2022

Issue link: https://www.e-digitaleditions.com/i/1483907

Contents of this Issue

Navigation

Page 2 of 36

wuxibiologics.com GMP Production Where and When You Need It. Quality. Expertise. Performance. Capacity. These are the four cornerstones WuXi Biologics provides to its clients with every biologic produced. We are operating 15 state-of-the-art world-class cGMP DS facilities and another 11 DP facilities across four countries while expanding globally over the next few years. WuXi Biologics provides high-quality DS and DP where and when you need it. China • Germany • Ireland • Singapore • United States Let's Get Started. Capabilities Include: Drug Substance (DS) Manufacture • 262,000 L bioreactor capacity, expanding to 580,000 L by 2026 • Single-use/disposable bioreactors • Scale-out manufacturing paradigm • Fed-batch or continuous cell culture Drug Product (DP) Manufacture • Fully-automated, robotic and gloveless isolator • Vial, pre-filled syringe, auto-injector and liquid or lyophilization fill options • Ready-to-Use (RTU) containers and closures available YOUR GLOBAL DUAL SOURCE FOR BIOLOGICS

Articles in this issue

Links on this page

Archives of this issue

view archives of BioPharm International - November 2022 - BioPharm International - November 2022